J8,
The reason Biotron persist with using Interferon/Ribavirin as the SOC is because in Thailand where the clinical trials are being conducted it is the SOC. The more recent drugs sofosbuvir, ledipasvir, simeprevir etc are not approved, nor available treatments in Thailand. Given it is prohibitively expensive and difficult to conduct clinical trials in the heavily regulated US, Australia, UK what choice does any new drug developer have? In the real world - you have to work with what you've got.
J8, The reason Biotron persist with using Interferon/Ribavirin...
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.7¢ |
Change
-0.011(39.3%) |
Mkt cap ! $15.33M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.5¢ | 1.7¢ | $374.7K | 18.97M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 1266038 | 1.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.8¢ | 689330 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| BIT (ASX) Chart |